Research programme: RAGE monoclonal antibodies: AbbVie/CSL Behring

Drug Profile

Research programme: RAGE monoclonal antibodies: AbbVie/CSL Behring

Alternative Names: A-992400; A-992401

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories; CSL Behring
  • Developer AbbVie; CSL Behring
  • Class Monoclonal antibodies
  • Mechanism of Action Advanced glycosylation end-product receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alzheimer's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alzheimer's-disease in Germany (Parenteral)
  • 02 Jan 2013 Abbott spins out its pharmaceuticals business to new company called AbbVie
  • 13 Nov 2010 Preclinical trials in Alzheimer's disease in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top